For example, the first-in-class exportin-1 inhibitor selinexor, which is FDA-approved for the treatment of multiple myeloma and DLBCL, downregulates the surface expression of HLA-E on both lymphoma cell lines [116] and primary CLL cells [70], resulting in improved NK cell function against these targets. This evidence concerns the gene HLA-E and B-cell chronic lymphocytic leukemia.